Edition:
United States

Biohit Oyj (BIOBV.HE)

BIOBV.HE on Helsinki Stock Exchange

5.40EUR
12:29pm EDT
Change (% chg)

€0.03 (+0.56%)
Prev Close
€5.37
Open
€5.45
Day's High
€5.45
Day's Low
€5.39
Volume
14,910
Avg. Vol
10,141
52-wk High
€6.85
52-wk Low
€4.71

Latest Key Developments (Source: Significant Developments)

Biohit H2 operating loss flat at EUR 1.3 mln
Monday, 20 Feb 2017 02:30am EST 

Biohit Oyj : H2 net sales 4.4 million euros ($4.67 million) versus 2.5 million euros year ago . H2 operating loss 1.3 million euros versus loss 1.4 million euros year ago . Board of directors proposes to annual general meeting that no dividend be paid for financial year . China's operations are in Biohit's focus in 2017 . Expects to complete reduction of joint venture share capital during Q1 of 2017 . Estimates its non-comparable operating result to turn clearly positive for 2017 . Net sales growth is expected in 2017 .Company does not assess when comparable result will turn to positive.  Full Article

Biohit and R-kioski to start cooperation
Wednesday, 16 Nov 2016 02:30am EST 

Biohit Oyj : Biohit Oyj and R-kioski to start cooperation . R-Kioski will sell and promote gift cards for Biohit's health checks for its consumers in R-kioski convenience stores across Finland .Agreement will enter into force immediately and will start with launch during December 2016.  Full Article

Glomedics to distribute Biohit lactose intolerance test in South Korea
Friday, 2 Sep 2016 08:00am EDT 

Biohit Oyj :Says has signed agreement with Glomedics for distribution of Biohit Lactose Intolerance Quick Test in South Korea.  Full Article

Biohit signs distribution deal for GA-map dysbiosis test in China
Monday, 22 Aug 2016 02:30am EDT 

Biohit Oyj :Beijing Huayihuilang Medical Instrument Co., Ltd. to distribute GA-map dysbiosis test in China.  Full Article

Biohit H1 operating loss widening to SEK 2.1 million
Thursday, 18 Aug 2016 02:30am EDT 

Biohit Oyj : H1 net sales 3.8 million euros versus 3.5 million euros year ago . H1 operating loss 2.1 million euros versus loss 1.5 million euros year ago . Net sales growth is expected in 2016 .Says does not publish forecasts when result will turn to positive.  Full Article

Biohit: Population-based screening study for gastric cancer risk is completed
Monday, 1 Aug 2016 06:45am EDT 

Biohit Oyj : A population-based screening study for gastric cancer risk has been completed in Russia .The study results confirm the previous study results showing that GastroPanel detects patients at increased risk for developing gastric cancer.  Full Article

Biohit and Pyynikin Craft Brewery to start cooperation
Wednesday, 6 Jul 2016 02:30am EDT 

Biohit Oyj : Biohit Oyj and Pyynikin Craft Brewery to start cooperation .Pyynikin Craft Brewery will launch a new beer brand called Pyynikin Vapaa (Pyynikki's Free) during the summer.  Full Article

Biohit signs distribution agreement with Pooyandegan Pezeshki Pardis
Wednesday, 18 May 2016 02:30am EDT 

Biohit Oyj :Biohit Oyj and Pooyandegan Pezeshki Pardis have signed an agreement for the distribution of the Biohit Unified GastroPanel test in Iran.  Full Article

Biohit signs distribution agreement for China
Thursday, 17 Mar 2016 06:45am EDT 

Biohit Oyj:Says the company and Tianjin Jingsheng Biological Technology Development Co. Ltd have signed a distributor agreement for the distribution of the Biohit Calprotectin ELISA test in China.  Full Article

Biohit and OnSite Diagnostic Labs India Pvt Ltd. to start co-operation
Wednesday, 2 Mar 2016 05:30am EST 

Biohit Oyj:Biohit and OnSite Diagnostic Labs India Pvt Ltd. have signed distributor agreement​.‍Agreement is for Biohit diagnostic portfolio in India​.  Full Article

More From Around the Web

BRIEF-Biohit H2 operating loss flat at EUR 1.3 mln

* H2 net sales 4.4 million euros ($4.67 million) versus 2.5 million euros year ago